Autolus Therapeutics (AUTL) Stock Forecast, Price Target & Predictions
AUTL Stock Forecast
Autolus Therapeutics stock forecast is as follows: an average price target of $8.87 (represents a 216.79% upside from AUTL’s last price of $2.80) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
AUTL Price Target
AUTL Analyst Ratings
Buy
Autolus Therapeutics Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Nov 18, 2024 | Graig Suvannavejh | Goldman Sachs | $7.60 | $3.03 | 150.99% | 171.43% |
May 20, 2024 | Yanan Zhu | Wells Fargo | $8.00 | $4.39 | 82.23% | 185.71% |
Apr 08, 2024 | Asthika Goonewardene | Truist Financial | $11.00 | $5.53 | 98.92% | 292.86% |
Mar 15, 2024 | Asthika Goonewardene | Truist Financial | $10.00 | $5.82 | 71.82% | 257.14% |
10
Autolus Therapeutics Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | 1 | 1 | 4 |
Avg Price Target | $7.60 | $7.60 | $9.15 |
Last Closing Price | $2.80 | $2.80 | $2.80 |
Upside/Downside | 171.43% | 171.43% | 226.79% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Nov 18, 2024 | Goldman Sachs | - | Buy | Upgrade |
Jun 17, 2024 | Needham | Buy | Buy | Hold |
May 20, 2024 | Wells Fargo | Overweight | Overweight | Hold |
Mar 18, 2024 | Needham | Buy | Buy | Hold |
Mar 08, 2023 | Piper Sandler | Buy | Buy | Hold |
Dec 09, 2022 | Needham | Buy | Buy | Hold |
10
Autolus Therapeutics Financial Forecast
Autolus Therapeutics Revenue Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $406.00K | - | $1.29M | $3.83M | $2.37M | - | - | $823.00K | - | $1.51M | $269.00K | - | $242.00K | $293.00K | $338.00K | $309.00K | $297.00K |
Avg Forecast | $38.32M | $31.78M | $23.61M | $18.35M | $16.14M | $12.82M | $9.95M | $7.53M | $3.97M | $155.00K | $93.75K | $29.01M | $358.40K | $624.80K | $136.50K | $379.29K | $11.18M | $144.29K | $240.56K | $171.43K | $6.58M | $291.68K | $212.15K | $344.63K | $293.89K | $303.11K | $327.00K | $500.00K | $450.00K | $480.00K |
High Forecast | $38.32M | $31.78M | $23.61M | $18.35M | $16.14M | $12.82M | $9.95M | $7.53M | $3.97M | $155.00K | $93.88K | $29.01M | $358.40K | $624.90K | $136.50K | $379.29K | $11.18M | $144.29K | $240.56K | $171.43K | $6.58M | $291.68K | $212.15K | $344.63K | $293.89K | $303.11K | $327.00K | $500.00K | $450.00K | $480.00K |
Low Forecast | $38.32M | $31.78M | $23.61M | $18.35M | $16.14M | $12.82M | $9.95M | $7.53M | $3.97M | $155.00K | $93.63K | $29.01M | $358.40K | $624.70K | $136.50K | $379.29K | $11.18M | $144.29K | $240.56K | $171.43K | $6.58M | $291.68K | $212.15K | $344.63K | $293.89K | $303.11K | $327.00K | $500.00K | $450.00K | $480.00K |
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 15 | 10 | 16 | 8 | 11 | 7 | 11 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.65% | - | 3.41% | 0.34% | 16.42% | - | - | 0.13% | - | 7.10% | 0.78% | - | 0.80% | 0.90% | 0.68% | 0.69% | 0.62% |
Forecast
Autolus Therapeutics EBITDA Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 15 | 10 | 16 | 8 | 11 | 7 | 11 |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-40.89M | $-44.01M | $-42.47M | $-33.21M | $-26.45M | $-45.28M | $-45.80M | $-38.83M | $-45.50M | $-37.91M | $-35.48M | $-36.87M | $-45.67M | $-41.24M | $-38.28M | $-37.30M | $-37.69M | $-34.48M |
Avg Forecast | $-38.32M | $-31.78M | $-23.61M | $-18.35M | $-16.14M | $-12.82M | $-9.95M | $-7.53M | $-3.97M | $-155.00K | $-93.75K | $-61.91M | $-358.40K | $-624.80K | $-136.50K | $-56.28M | $-25.62M | $-144.29K | $-240.56K | $-44.49M | $-6.58M | $-291.68K | $-212.15K | $-41.68M | $-293.89K | $-303.11K | $-327.00K | $-38.42M | $-450.00K | $-480.00K |
High Forecast | $-38.32M | $-31.78M | $-23.61M | $-18.35M | $-16.14M | $-12.82M | $-9.95M | $-7.53M | $-3.97M | $-155.00K | $-93.63K | $-49.53M | $-358.40K | $-624.70K | $-136.50K | $-45.03M | $-20.50M | $-144.29K | $-240.56K | $-35.59M | $-6.58M | $-291.68K | $-212.15K | $-33.35M | $-293.89K | $-303.11K | $-327.00K | $-30.74M | $-450.00K | $-480.00K |
Low Forecast | $-38.32M | $-31.78M | $-23.61M | $-18.35M | $-16.14M | $-12.82M | $-9.95M | $-7.53M | $-3.97M | $-155.00K | $-93.88K | $-74.29M | $-358.40K | $-624.90K | $-136.50K | $-67.54M | $-30.75M | $-144.29K | $-240.56K | $-53.39M | $-6.58M | $-291.68K | $-212.15K | $-50.02M | $-293.89K | $-303.11K | $-327.00K | $-46.10M | $-450.00K | $-480.00K |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 114.08% | 70.44% | 311.11% | 0.59% | 1.03% | 313.84% | 190.41% | 0.87% | 6.92% | 129.96% | 167.23% | 0.88% | 155.39% | 136.06% | 117.06% | 0.97% | 83.76% | 71.83% |
Forecast
Autolus Therapeutics Net Income Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 15 | 10 | 16 | 8 | 11 | 7 | 11 |
Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-77.17M | $-45.85M | $-45.55M | $-39.81M | $-26.95M | $-42.77M | $-42.06M | $-37.06M | $-41.67M | $-33.99M | $-33.17M | $-33.27M | $-42.86M | $-37.31M | $-32.05M | $-29.87M | $-40.94M | $-27.25M |
Avg Forecast | $-39.02M | $-46.92M | $-58.41M | $-56.42M | $-54.10M | $-58.54M | $-61.20M | $-61.20M | $-53.74M | $-57.02M | $-51.75M | $-59.09M | $-67.29M | $-66.40M | $-59.46M | $-53.72M | $-23.40M | $-125.50M | $-111.73M | $-42.47M | $-102.57M | $-134.40M | $-132.63M | $-37.15M | $-203.66M | $-187.99M | $-188.58M | $-35.52M | $-196.41M | $-228.78M |
High Forecast | $-39.02M | $-46.92M | $-58.41M | $-56.42M | $-54.10M | $-58.54M | $-61.20M | $-61.20M | $-12.80M | $-57.02M | $-51.75M | $-47.27M | $-59.52M | $-66.40M | $-59.46M | $-42.98M | $-18.72M | $-125.50M | $-111.73M | $-33.97M | $-102.57M | $-134.40M | $-132.63M | $-29.72M | $-203.66M | $-187.99M | $-188.58M | $-28.42M | $-196.41M | $-228.78M |
Low Forecast | $-39.02M | $-46.92M | $-58.41M | $-56.42M | $-54.10M | $-58.54M | $-61.20M | $-61.20M | $-84.45M | $-57.02M | $-51.75M | $-70.91M | $-75.05M | $-66.40M | $-59.46M | $-64.46M | $-28.08M | $-125.50M | $-111.73M | $-50.96M | $-102.57M | $-134.40M | $-132.63M | $-44.58M | $-203.66M | $-187.99M | $-188.58M | $-42.63M | $-196.41M | $-228.78M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.15% | 0.69% | 0.77% | 0.74% | 1.15% | 0.34% | 0.38% | 0.87% | 0.41% | 0.25% | 0.25% | 0.90% | 0.21% | 0.20% | 0.17% | 0.84% | 0.21% | 0.12% |
Forecast
Autolus Therapeutics SG&A Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 15 | 10 | 16 | 8 | 11 | 7 | 11 |
SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $15.73M | $10.61M | $11.12M | $9.28M | $7.41M | $8.23M | $8.27M | $7.99M | $7.59M | $8.30M | $7.24M | $8.74M | $9.01M | $9.84M | $8.51M | $7.61M | $9.92M | $8.61M |
Avg Forecast | $1.57B | $1.30B | $965.27M | $750.33M | $659.81M | $524.05M | $406.86M | $307.91M | $162.16M | $6.34M | $3.83M | $12.73M | $14.65M | $25.55M | $5.58M | $15.51M | $8.61M | $5.79M | $9.65M | $6.88M | $263.76M | $11.70M | $8.51M | $13.82M | $11.79M | $12.16M | $13.12M | $20.06M | $18.05M | $19.25M |
High Forecast | $1.57B | $1.30B | $965.27M | $750.33M | $659.81M | $524.05M | $406.86M | $307.91M | $162.16M | $6.34M | $3.84M | $15.28M | $14.65M | $25.55M | $5.58M | $15.51M | $10.33M | $5.79M | $9.65M | $6.88M | $263.76M | $11.70M | $8.51M | $13.82M | $11.79M | $12.16M | $13.12M | $20.06M | $18.05M | $19.25M |
Low Forecast | $1.57B | $1.30B | $965.27M | $750.33M | $659.81M | $524.05M | $406.86M | $307.91M | $162.16M | $6.34M | $3.83M | $10.19M | $14.65M | $25.54M | $5.58M | $15.51M | $6.88M | $5.79M | $9.65M | $6.88M | $263.76M | $11.70M | $8.51M | $13.82M | $11.79M | $12.16M | $13.12M | $20.06M | $18.05M | $19.25M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.07% | 0.42% | 1.99% | 0.60% | 0.86% | 1.42% | 0.86% | 1.16% | 0.03% | 0.71% | 0.85% | 0.63% | 0.76% | 0.81% | 0.65% | 0.38% | 0.55% | 0.45% |
Forecast
Autolus Therapeutics EPS Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 15 | 10 | 16 | 8 | 11 | 7 | 11 |
EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.44 | $-0.26 | $-0.26 | $-0.23 | $-0.30 | $-0.47 | $-0.46 | $-0.41 | $-0.57 | $-0.47 | $-0.47 | $-0.53 | $-0.69 | $-0.72 | $-0.62 | $-0.60 | $-0.82 | $-0.61 |
Avg Forecast | $-0.15 | $-0.18 | $-0.22 | $-0.21 | $-0.20 | $-0.22 | $-0.23 | $-0.23 | $-0.20 | $-0.21 | $-0.19 | $-0.08 | $-0.25 | $-0.25 | $-0.22 | $-0.27 | $-0.27 | $-0.47 | $-0.42 | $-0.49 | $-0.39 | $-0.51 | $-0.50 | $-0.60 | $-0.77 | $-0.71 | $-0.71 | $-0.74 | $-0.74 | $-0.86 |
High Forecast | $-0.15 | $-0.18 | $-0.22 | $-0.21 | $-0.20 | $-0.22 | $-0.23 | $-0.23 | $-0.05 | $-0.21 | $-0.19 | $-0.08 | $-0.22 | $-0.25 | $-0.22 | $-0.27 | $-0.27 | $-0.47 | $-0.42 | $-0.49 | $-0.39 | $-0.51 | $-0.50 | $-0.60 | $-0.77 | $-0.71 | $-0.71 | $-0.74 | $-0.74 | $-0.86 |
Low Forecast | $-0.15 | $-0.18 | $-0.22 | $-0.21 | $-0.20 | $-0.22 | $-0.23 | $-0.23 | $-0.32 | $-0.21 | $-0.19 | $-0.08 | $-0.28 | $-0.25 | $-0.22 | $-0.27 | $-0.27 | $-0.47 | $-0.42 | $-0.49 | $-0.39 | $-0.51 | $-0.50 | $-0.60 | $-0.77 | $-0.71 | $-0.71 | $-0.74 | $-0.74 | $-0.86 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.74% | 1.04% | 1.16% | 0.86% | 1.12% | 1.00% | 1.10% | 0.83% | 1.48% | 0.93% | 0.94% | 0.88% | 0.90% | 1.02% | 0.87% | 0.81% | 1.11% | 0.71% |
Forecast
Autolus Therapeutics Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
XFOR | X4 Pharmaceuticals | $0.34 | $3.67 | 979.41% | Buy |
INZY | Inozyme Pharma | $2.79 | $14.67 | 425.81% | Buy |
ANEB | Anebulo Pharmaceuticals | $1.52 | $6.00 | 294.74% | Buy |
AUTL | Autolus Therapeutics | $2.80 | $8.87 | 216.79% | Buy |
ABOS | Acumen Pharmaceuticals | $2.37 | $7.00 | 195.36% | Buy |
DAWN | Day One Biopharmaceuticals | $13.62 | $38.80 | 184.88% | Buy |
LYRA | Lyra Therapeutics | $0.18 | $0.50 | 177.78% | Hold |
APLS | Apellis Pharmaceuticals | $27.49 | $74.50 | 171.01% | Buy |
RZLT | Rezolute | $5.01 | $13.50 | 169.46% | Buy |
TERN | Terns Pharmaceuticals | $5.60 | $14.25 | 154.46% | Buy |
CGEM | Cullinan Oncology | $12.58 | $31.50 | 150.40% | Buy |
CELC | Celcuity | $12.78 | $31.50 | 146.48% | Buy |
BOLT | Bolt Biotherapeutics | $0.57 | $1.00 | 75.44% | Hold |
AMLX | Amylyx Pharmaceuticals | $5.23 | $6.67 | 27.53% | Buy |
VECT | VectivBio | $16.87 | $18.00 | 6.70% | Buy |
IKNA | Ikena Oncology | $1.70 | $1.33 | -21.76% | Buy |